Nevro Corp (NYSE:NVRO) CFO Andrew H. Galligan Sells 18,522 Shares

Nevro Corp (NYSE:NVRO) CFO Andrew H. Galligan sold 18,522 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $103.70, for a total value of $1,920,731.40. The sale was disclosed in a filing with the SEC, which is available at this link.

NYSE:NVRO traded down $0.59 during trading on Thursday, reaching $105.65. The company’s stock had a trading volume of 6,502 shares, compared to its average volume of 431,254. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of -64.90 and a beta of 0.21. The company has a debt-to-equity ratio of 0.91, a quick ratio of 4.54 and a current ratio of 5.87. The firm has a 50 day moving average of $86.76 and a 200-day moving average of $73.43. Nevro Corp has a 12 month low of $34.75 and a 12 month high of $108.20.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.27. The firm had revenue of $100.16 million during the quarter, compared to the consensus estimate of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) EPS. Equities research analysts forecast that Nevro Corp will post -3.74 earnings per share for the current fiscal year.

NVRO has been the subject of several recent research reports. Bank of America upped their price target on Nevro from $70.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Zacks Investment Research upgraded Nevro from a “sell” rating to a “hold” rating and set a $67.00 price target for the company in a report on Tuesday, August 13th. Morgan Stanley upped their price target on Nevro from $76.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. UBS Group upped their price target on Nevro from $44.00 to $77.00 and gave the stock a “sell” rating in a report on Friday, November 8th. Finally, Northland Securities set a $65.00 price target on Nevro and gave the stock a “hold” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $86.83.

A number of large investors have recently made changes to their positions in the business. Invesco Ltd. grew its stake in shares of Nevro by 316.2% during the 2nd quarter. Invesco Ltd. now owns 1,970,969 shares of the medical equipment provider’s stock worth $127,778,000 after acquiring an additional 1,497,455 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Nevro by 91.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,078,635 shares of the medical equipment provider’s stock worth $199,588,000 after acquiring an additional 1,470,807 shares during the period. Perceptive Advisors LLC grew its stake in shares of Nevro by 172.9% during the 2nd quarter. Perceptive Advisors LLC now owns 1,137,765 shares of the medical equipment provider’s stock worth $73,761,000 after acquiring an additional 720,816 shares during the period. Nuveen Asset Management LLC bought a new position in shares of Nevro during the 2nd quarter worth $26,818,000. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of Nevro by 11.7% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,067,400 shares of the medical equipment provider’s stock worth $134,029,000 after acquiring an additional 216,680 shares during the period.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Read More: What is the G-20?

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.